AT
ALXN

Arden Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Arden Trust’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,172
Closed -$1.28M – 331
2020
Q4 		$1.28M Sell
8,172
-1,180
-13% -$152K 0.21% 98
2020
Q3 		$1.07M Buy
9,352
+776
+9% +$83.7K 0.19% 106
2020
Q2 		$963K Buy
8,576
+112
+1% +$11.9K 0.18% 114
2020
Q1 		$760K Buy
8,464
+1,111
+15% +$109K 0.15% 123
2019
Q4 		$795K Sell
7,353
-838
-10% -$89.6K 0.12% 162
2019
Q3 		$802K Buy
8,191
+35
+0.4% +$3.94K 0.13% 156
2019
Q2 		$1.07M Buy
8,156
+51
+0.6% +$6.57K 0.18% 125
2019
Q1 		$1.09M Buy
8,105
+2,421
+43% +$301K 0.18% 134
2018
Q4 		$553K Sell
5,684
-1,518
-21% -$179K 0.1% 191
2018
Q3 		$1M Sell
7,202
-287
-4% -$36K 0.16% 138
2018
Q2 		$930K Buy
7,489
+1,444
+24% +$169K 0.15% 144
2018
Q1 		$673K Buy
6,045
+298
+5% +$35.6K 0.1% 187
2017
Q4 		$687K Buy
5,747
+482
+9% +$58.7K 0.1% 181
2017
Q3 		$738K Sell
5,265
-124
-2% -$16.8K 0.11% 184
2017
Q2 		$655K Sell
5,389
-418
-7% -$48.6K 0.1% 195
2017
Q1 		$704K Sell
5,807
-3,459
-37% -$446K 0.11% 177
2016
Q4 		$1.13M Buy
9,266
+529
+6% +$64.7K 0.17% 119
2016
Q3 		$1.07M Sell
8,737
-1,791
-17% -$231K 0.16% 122
2016
Q2 		$1.23M Buy
10,528
+4,608
+78% +$654K 0.09% 208
2016
Q1 		$824K Buy
5,920
+4,294
+264% +$630K 0.07% 284
2015
Q4 		$310K Buy
1,626
+56
+4% +$9.78K 0.03% 456
2015
Q3 		$246K Buy
+1,570
New +$286K 0.02% 581

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arden Trust's ALXN Position: Q1 2021 in Review

Arden Trust sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 8,172 shares — an estimated $1.28M sold.

Arden Trust first reported a position in ALXN in Q3 2015 and held it in 22 quarters. The position peaked at $1.28M in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Arden Trust reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Arden Trust sold 8,172 Alexion Pharmaceuticals shares in Q1 2021, an estimated $1.28M.
  • Arden Trust first reported a position in Alexion Pharmaceuticals in Q3 2015 and held it in 22 quarters.
  • Arden Trust's Alexion Pharmaceuticals position peaked at $1.28M in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Arden Trust's 13F filing for Q1 2021, filed 23 Apr 2021.